HURA TuHURA Biosciences, Inc./NV
Price Chart
Executive Summary
TuHURA Biosciences reported Q1 2026 financial results with no revenue and a net loss per share of -$0.17, missing the consensus estimate of -$0.11. The company highlighted a $50 million credit facility established in April 2026 to extend cash runway into 2028, and FDA Orphan Drug Designation for IFx-2.0 in melanoma. The filing is neutral as it is a pre-revenue clinical-stage biotech with no material change in fundamentals; the credit facility provides non-dilutive capital but carries a 12% interest rate.
Actionable Insight
Monitor upcoming FDA IND meeting for TBS-2025 and Phase 3 enrollment updates for IFx-2.0. The $50M credit facility reduces near-term dilution risk but carries a 12% interest cost. Key catalysts are binary clinical trial readouts expected in 2H 2027.
Key Facts
- Cash and cash equivalents of $6.3 million at March 31, 2026
- Common shares outstanding approximately 63.6 million
- Research and development expenses $5.2 million for Q1 2026 vs $4.6 million in Q1 2025
- General and administrative expenses $2.3 million for Q1 2026 vs $2.0 million in Q1 2025
- Net cash outflows from operating activities ($4.4) million for Q1 2026 vs ($4.7) million in Q1 2025
- Net cash flows from financing activities $7.2 million for Q1 2026 vs ($0.5) million in Q1 2025
- Established a $50 million credit facility in April 2026 with 12% annual interest, maturing April 21, 2031
- Received FDA Orphan Drug Designation for IFx-2.0 in stage IIB to stage IV cutaneous melanoma
- Phase 3 trial of IFx-2.0 in Merkel Cell Carcinoma enrollment completion expected in 2H 2027
- EPS of -$0.17 missed consensus estimate of -$0.11
Financial Impact
No revenue; cash burn of $4.4M in operating activities; $50M credit facility provides runway into 2028
Risk Factors
- Pre-revenue clinical-stage company with no approved products
- Cash and equivalents of $6.3M may require additional financing before Phase 3 data readout in 2H 2027
- Credit facility carries 12% annual interest, increasing financial leverage
- Clinical trial risks: patient enrollment, data outcomes, regulatory interactions
- EPS miss of 54.5% vs consensus may pressure stock
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-227204 |
| Document: hura-ex99_1.htm | 0001193125-26-227204 |
| Document: 0001193125-26-227204-index-headers.html | 0001193125-26-227204 |
| Document: 0001193125-26-227204-index.html | 0001193125-26-227204 |
| Document: 0001193125-26-227204.txt | 0001193125-26-227204 |
| 8-K Data (Synthetic) | 0001193125-26-227204 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
14d ago
|
8-K
| $2.24 $1.97 | ▼ −12.28% | ▼ −9.53% | $2.32 (+3.57%) |
|
May 15, 2026
28d ago
|
8-K
| $2.55 $2.45 | ▼ −3.92% | ▼ −5.54% | $2.32 (−9.02%) |
|
Apr 22, 2026
7w ago
|
8-K
| $2.68 $2.15 | ▼ −19.96% | ▼ −20.02% | $2.32 (−13.43%) |
|
Apr 8, 2026
9w ago
|
424B5
| $1.96 $2.96 | ▼ −51.02% | ▼ −47.83% | $2.32 (−18.37%) |
|
Apr 8, 2026
9w ago
|
8-K
| $1.96 $2.96 | ▲ +51.02% | ▲ +47.83% | $2.32 (+18.37%) |
|
Apr 1, 2026
10w ago
|
8-K
| $1.62 $1.96 | ▼ −20.99% | ▼ −17.22% | $2.32 (−43.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access